Results from the first major business survey for 2021 by the Chambers of Commerce on Brexit found that half (49%) of exporters are facing difficulties in adapting to the changes in the trade of goods following the ratification of the UK-EU Trade and Cooperation Agreement (TCA) on 1 January 2021.
News
Cambridge, UK, and New York City, USA, 11 February 2021: Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announced the start of a clinical trial of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumors.
Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.
Cambridge, UK, 09 February 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of John Montana, PhD, as a Non-Executive Director. Expansion of the Board of Directors will support the Company’s further growth.
EARLY-STAGE LIFE SCIENCE VENTURES INVITED TO APPLY FOR SPECIALIST SUPPORT AHEAD OF INVESTMENT ROUNDS
“The programme has been specially designed to support MedTech, Diagnostic and Digital Health, including service delivery, ventures to successfully engage investors needed to support their future growth, commercialise scientific discovery and solve global health and environmental challenges. If the last twelve months have taught us anything it is that solutions to many of our current problems are within the hands of the scientific community. Our ultimate aim is to help them make sure those solutions make it out of the lab and into the world”.
Research Triangle Park, NC, USA and Cambridge, UK, 4 February 2021 -- Inivata, a leader in liquid biopsy, today announces it has raised $35 million (£25.7 million) in a second close of a Series C financing round.
Cambridge, United Kingdom – 3 February 2021 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, announces a collaboration with Gabriel Precision Oncology Limited (“Gabriel”), a spin-out company from the University of Glasgow.
- Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled receptors (GPCRs)
- Collaboration combines Sosei Heptares’ leading structure-based drug design platform with Metrion Biosciences’ ion channel expertise
- Joint drug discovery program to focus on a single ion channel that is a well-validated target for neurological diseases
AMSBIO has expanded its range of primary human cancer cells sourced from a wide variety of tissue types that allow the study of cancer in a more in vivo like fashion.
The deadline for compliance with the EU Medical Device Regulations is looming. On the 25th of May 2017, new EU regulations for medical devices and in vitro diagnostic medical devices entered into force, giving medical device companies a 3 / 5 - year transition period to achieve compliance. Whilst the MDR has been delayed as a result of the COVID-19 pandemic, by May 2021 medical devices must adhere to the updated regulations, transitioning from the Medical Device Directive (MDD) to the Medical Device Regulations (MDR).